<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04137029</url>
  </required_header>
  <id_info>
    <org_study_id>PSRI04-19</org_study_id>
    <nct_id>NCT04137029</nct_id>
  </id_info>
  <brief_title>Methacholine, Long-acting M-cholinolytic and beta2-agonist on the Activity of Beta-receptors in Healthy Volunteers</brief_title>
  <official_title>Effect of Methacholine, Long-acting M-cholinolytic and beta2-agonist on the Binding Activity of Beta-receptors in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Federal State Budgetary Institution, Pulmonology Scientific Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Moscow State University of Medicine and Dentistry</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Medical Research Center for Cardiology, Ministry of Health of Russian Federation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Branch of Shemyakin-Ovchinnikov Institute of Bioorganic chemistry of RAS</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Federal State Budgetary Institution, Pulmonology Scientific Research Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Interventional open-labeled study in parallel groups is aimed to evaluate changes of beta
      receptors in healthy volunteers under the influence of inhaled metacholine, long-acting
      anticholinergics and beta-agonists using modified radioligand method.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Long-acting beta2-agonists and anticholinergics are main drugs in therapy of chronic
      obstructive pulmonary disease . Beta-agonists exert their bronchodilatory effects via Î²2
      adrenoceptors located on airway smooth muscle cells. Anticholinergics block mainly
      M3-cholinoreceptors located in the airways, thus inhibiting bronchoconstriction. Metacholine
      blocks M2-cholinoreceptors thus inducing bronchoconstriction. It is known, that muscarine and
      beta-receptors interact with each other, but the detailed mechanism is unknown. For
      evaluating the binding activity of beta-receptors after inhalation of these drugs the
      modified radioligand method was used.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 24, 2019</start_date>
  <completion_date type="Anticipated">October 2020</completion_date>
  <primary_completion_date type="Anticipated">July 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>There are two groups: the first group is smokers, the second group is non - smokers. The participants of both groups will receive metacholine on the first visit, formoterol 12 micrograms on the second visit, then tiotropium bromide 18 mkg on the third visit.</intervention_model_description>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline beta-receptor binding activity at 60 min after the inhalation of formoterol or tiotropium.</measure>
    <time_frame>Baseline (pre-dose), 60 minutes</time_frame>
    <description>Beta-receptor binding activity will be measured with modified radioligand method before and after 60 min after the inhalation of formoterol or tiotropium</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline beta-receptor binding activity at 40 min after the challenge test with metacholine.</measure>
    <time_frame>Baseline (pre-dose), 40 minutes</time_frame>
    <description>Beta-receptor binding activity will be measured with modified radioligand method before and after 40 min after the challenge test with metacholine.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparison of beta-receptor binding activity measured with modified radioligand after formoterol and tiotropium.</measure>
    <time_frame>Baseline (pre-dose), 60 minutes</time_frame>
    <description>Difference of change of beta-receptor binding activity measured with modified radioligand method before and after 60 min after the inhalation of formoterol and tiotropium.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of beta-receptor binding activity measured with modified radioligand method after formoterol or tiotropium in smokers and non-smokers.</measure>
    <time_frame>Baseline (pre-dose), 60 minutes</time_frame>
    <description>Difference of change of beta-receptor binding activity measured with modified radioligand method before and after 60 min after the inhalation of formoterol or tiotropium in smokers and non-smokers.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of beta-receptor binding activity measured with modified radioligand after metacholine</measure>
    <time_frame>Baseline (pre-dose), 40 minutes</time_frame>
    <description>Difference of change of beta-receptor binding activity measured with modified radioligand method before and after inhalation of metacholine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of beta-receptor binding activity measured with modified radioligand method after inhalation of metacholine in smokers and non-smokers.</measure>
    <time_frame>Baseline (pre-dose), 40 minutes</time_frame>
    <description>Difference of change of beta-receptor binding activity measured with modified radioligand method before and after inhalation of metacholine</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Health, Subjective</condition>
  <condition>Hyperreactivity, Bronchial</condition>
  <arm_group>
    <arm_group_label>smoking</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy smoking volunteers</description>
  </arm_group>
  <arm_group>
    <arm_group_label>non-smoking</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy non-smoking volunteers</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Formoterol</intervention_name>
    <description>The participants will receive inhalation of formoterol 12 micrograms</description>
    <arm_group_label>non-smoking</arm_group_label>
    <arm_group_label>smoking</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tiotropium Bromide</intervention_name>
    <description>The participants will receive inhalation of tiotropium bromide 18 mkg once</description>
    <arm_group_label>non-smoking</arm_group_label>
    <arm_group_label>smoking</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>metacholine test</intervention_name>
    <description>The participants will receive inhalation of metacholine once</description>
    <arm_group_label>non-smoking</arm_group_label>
    <arm_group_label>smoking</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        1 Provision of signed and dated informed consent form 2. Healthy male or female, aged 18-60
        years

        Exclusion Criteria:

          -  Participants unable to perform spirometry

          -  Exacerbation respiratory infection within the previous four weeks

          -  Hypersensitivity or allergy to formoterol, metacholine or tiotropium bromide

          -  Females who are currently pregnant and lactating

          -  major surgery in the last 6 months

          -  Refusal to participate

          -  Currently participating in another clinical study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kirill A Zykov, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Federal State Budgetary Institution, Pulmonology Scientific Research Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kirill A Zykov, Prof</last_name>
    <phone>+79257729462</phone>
    <email>kirillaz@inbox.ru</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Anna V Eremenko</last_name>
    <phone>+79265598031</phone>
    <email>a_nn87@list.ru</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Kirill Zykov</name>
      <address>
        <city>Moscow</city>
        <zip>115682</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kirill Zykov, Prof</last_name>
      <phone>+74953956393</phone>
      <email>pulmo_fmba@mail.ru</email>
    </contact>
    <contact_backup>
      <last_name>Anna Eremenko</last_name>
      <phone>+79265598031</phone>
      <email>a_nn87@list.ru</email>
    </contact_backup>
    <investigator>
      <last_name>Ann Eremenko</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <results_reference>
    <citation>Agapova OY, Skoblov YS, Zykov KA, Rvacheva AV, Beilina VB, Masenko VP, Chazova IE. [Radioligand Method of Assessment of Î²-Adrenoceptor's Activity on Human T-Lymphocytes]. Bioorg Khim. 2015 Sep-Oct;41(5):592-8. Russian.</citation>
    <PMID>26762097</PMID>
  </results_reference>
  <results_reference>
    <citation>Agapova OY, Skoblov YS, Tkachev GA, Mironova NA, Golitsyn SP, Masenko VP, Chazova IE, Zykov KA. [Changes in the receptor activity of Î²2-adrenoreceptors of human T-lymphocytes under the effect of Î²2-agonists]. Mol Biol (Mosk). 2016 Nov-Dec;50(6):999-1006. doi: 10.7868/S0026898416050025. Russian.</citation>
    <PMID>28064316</PMID>
  </results_reference>
  <results_reference>
    <citation>Smolyakova E.V., Skoblov Y.S., Skoblova N.A., Agapova O.Y., Ambat'ello L.G., Klimova A.A., Kuznetsova T.V., Masenko V.P., Nistor S.Yu., Rvacheva A.V., Chazova I.E., Zykov K.A. Specificity and Selectivity of the Modified Radioligand Method for Assessment of Î²1-Adrenoreceptor's Binding Activity on Human T-Lymphocytes. Russian Journal of Bioorganic Chemistry 45(3): 295-301, 2019</citation>
  </results_reference>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>October 11, 2019</study_first_submitted>
  <study_first_submitted_qc>October 22, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 23, 2019</study_first_posted>
  <last_update_submitted>October 22, 2019</last_update_submitted>
  <last_update_submitted_qc>October 22, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 23, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>beta-receptors</keyword>
  <keyword>metacholine</keyword>
  <keyword>formoterol</keyword>
  <keyword>tiotropium</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bronchial Hyperreactivity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bromides</mesh_term>
    <mesh_term>Formoterol Fumarate</mesh_term>
    <mesh_term>Tiotropium Bromide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

